NCT02209948

Temozolomide 12 Cycles Versus 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma.

Clinical Trial Phase IIB Randomized, Multicenter, of Continuation or Non Continuation With 6 Cycles of Temozolomide After the First 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 166 (actual)
• Sponsor: Grupo Español de Investigación en Neurooncología · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to show if prolonging treatment with temozolomide to 12 cycles improve progression-free survival in patients with glioblastoma included in this study, randomized according to o6-methylguanine-DNA-methyltransferase (MGMT) methylation status and residual disease or not, to receive an additional 6 cycles of temozolomide.

Conditions

• Glioblastoma

Interventions

Type	Name	Description
DRUG	Temozolomide

Timeline

• Start date: 2014-08-22
• Primary completion: 2019-06-01
• Completion: 2019-06-14
• First posted: 2014-08-06
• Last updated: 2021-01-12
• Results posted: 2021-01-12

Locations

20 sites across 1 country: Spain